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Role  of  photopheresis  in  the  treatment  of refractory  cellular
rejection in kidney  transplantation
Papel  de  la  fotoaféresis  en  el  tratamiento  del  rechazo  celular  agudo
refractario  en  trasplante  renal
To the Editor,
Extracorporeal photopheresis is an immunomodulatory tech-
nique based on the apoptotic effects of 8-methoxypsoralen
(8-MOP) and ultraviolet A (UVA) light on leukocytes. It is
widely used in T-cell-mediated diseases such as cutaneous
T-cell lymphoma, graft vs host disease, rheumatoid arthritis,
and systemic lupus erythematosus.1 Its use as prophylaxis
for acute rejection (AR) in lung and heart transplants seems
promising. However, there are few published articles on its
use in the treatment of acute cellular rejection refractory to
conventional treatment in renal transplant patients.
We  present the case of a 56-year-old man, who received
a cadaveric donor renal transplant in May 2013. Induc-
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monthly photopheresis, who had no improvement in renal
function, re-starting dialysis after a few months.3 However, in
other publications, more  frequent schedules have been asso-
ciated with improvement of renal function.4 Dall’Amico et al.
describe 4 patients with different types of cellular rejection,
who had previously received OKT3, with improvement in renal
function after the ﬁrst cycle of photopheresis treatment. Renal
function remained stable one year later, allowing a reduc-
tion in immunosuppressive therapy.5 Weekly, fortnightly, and
monthly schedules were used, up to a total of 19 sessions.
The different mechanisms by which photopheresis exerts
its beneﬁcial effects are not completely understood. It seems
to be related to triggering an immunomodulatory response
of alloreactive T cells exposed to 8-MOP and to UVA light. It
r
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3ion immunosuppression was with basiliximab, tacrolimus,
ycophenolate mofetil, and steroids. Renal function was
mmediate and maintained until 16 days post-transplant,
hen it deteriorated. Percutaneous renal biopsy was per-
ormed, demonstrating Banff type Ib acute cellular rejection.
nti-HLA, anti-MICA, and antiendothelial antibodies were
egative. The patient received salvage therapy with methyl-
rednisolone (3 × 500 mg)  and thymoglobulin (1.25 mg/kg;
otal cumulative dose, 410 mg)  without improvement. Seven-
een days later a second renal biopsy was performed, reported
s Banff type IIa acute cellular rejection, with mild inti-
al  arteritis. Given the clinical course and refractoriness to
reatment, with serum creatinine (SCr) of 2.97 mg/dL, pho-
opheresis was prescribed (14 sessions, once per week, with
herakos® UVAR XTS® System) along with nonspeciﬁc human
ammaglobulin (200 mg/kg; total dose, 80 g). Following this, a
rogressive improvement was seen in renal function, with SCr
f 2.3 mg/dL on discharge. Renal function remained stable for
 months, then deteriorated slightly, with a SCr of 2.62 mg/dL,
o it was decided to start a new course of photopheresis (6
essions, once weekly). There was a good response to treat-
ent (7 months later, the current SCr of 1.9 mg/dL) and no
reatment-related infectious complications were noted.
Prophylactic treatment with photopheresis in renal trans-
lant patients in addition to standard immunosuppression
as shown improvement in renal function at 6 months and
n increase in regulatory T-cells (Tregs).2 Regarding its use in
efractory AR, data from the literature are scarce, and, at times,
ontradictory. Horina et al. describe 3 patients treated with Please cite this article as: Fernández EJ, López C, Ramírez A, Guerra 
ratamiento del rechazo celular agudo refractario en trasplante renal. Nis likely that important roles are played by the synthesis of
interleukins (especially TNF, IL-10, and IL-6) and the increase
in regulatory T-cells (CD4+, CD25+ and FoxP3+), which increase
progressively in number after each session. These mecha-
nisms could explain why the beneﬁts in cutaneous T-cell
lymphoma are seen from the second or third month, while
in AR they can be seen after a few days.
Currently, photopheresis could be useful as salvage therapy
in cases of acute cellular rejection refractory to conventional
treatment in renal transplants. More extensive investigation
is needed to test its efﬁcacy and safety.
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Late  onset  of  de  novo  atypical  hemolytic–uremic  syndrome
presented on  a  simultaneous  pancreas  and  kidney
transplant recipient  successfully  treated  with  eculizumab
Presentacion  tardía  de  síndrome  hemolítico–urémico  atípico  de  novo
en  receptor  de  trasplante  reno-pancreático  resuelto  con  eculizumab
Dear Editor,
Atypical hemolytic–uremic syndrome (aHUS) is an extremely
rare, genetic, chronic, and progressive inﬂammatory disease1
caused by defects in complement system. These defects result
in systemic thrombotic microangiopathy involving damage
to multiple organ systems including renal dysfunction.1–7
Genetic mutations have been detected in around 50% of the
reported cases. Regarding renal transplant patients, expanded
criteria donors, infection by cytomegalovirus or BK, use of
CNI or m-TOR  inhibitors and antibody-mediated rejection
(AMR) have been related to de novo post-transplant aHUS.8
Graft failure is reported in 60–90% of patients within 1 year.10
Eculizumab is a monoclonal antibody that binds to C5 com-
plement protein avoiding the formation of the cell membrane
attack complex.6,7 We report herein a case of late onset of de
novo post-transplant aHUS on a simultaneous pancreas and
kidney recipient with severe systemic manifestations, with-
out presenting acute graft rejection, successfully treated with
limited doses of eculizumab remaining stable after one year
of follow-up.
A 46-year-old woman with end stage renal disease
secondary to type 1 Diabetes Mellitus underwent simul-
taneous pancreas and kidney transplant on October 2012
from deceased donor. Received induction with Basiliximab
and maintenance treatment with mycophenolate mofetil,
and vomiting, acute graft dysfunction (SCr 438 mol/L) and
thrombocytopenia (53 × 10 × 9/L). She developed progressive
anemia and thrombocytopenia and worsening of renal func-
tion requiring dialysis. Pancreas graft function remained
preserved. Thrombotyc microangiopathy (TMA)was detected
with lactate dehydrogenase (LDH) up to 1500 UI/L, unde-
tectable haptoglobin and schistocytes. C3 was low, ADAMTS 13
of 79% and Shigella toxin was negative. Urinary tract infection
by extended-spectrum beta-lactamase (ESBL)-klebsiella was
present. Initial biopsy conﬁrmed ﬁndings of TMA  with severe
tubulo-interstitial involvement and some focal glomerular
involvement, without features of acute rejection. Discontin-
uation of tacrolimus, antibiotic treatment with meropenem
and daily plasma exchange (PE) for 10 days were performed.
The patient did not respond to therapy. Second renal biopsy
showed persistent signs of TMA, worsening involvement of
glomeruli with mesangiolysis without rejection (Fig. 1). Treat-
ment with Eculizumab was started with 4 doses of 900 mg
Eculizumab iv on a weekly basis, showing improvement of
renal function, cessation of hemodialysis and hemolysis.
Genetic screening did not detect mutations on factor I, factor
H or factor MCP genes. Risk haplotype in heterozygosis for fac-
tor H and MCP genes were observed. Study of the complement
alternate pathway showed low factor C3, factor H, normal
expression of MCP  (membrane cofactor protein) and nega-
tive anti-factor H antibodies. A third biopsy was performedtacrolimus, and prednisone. Pancreatic and renal function
were stable, creatinine (SCr) of 110 mol/L. Tacrolimus through
levels remained between 6 and 8 ng/ml. Seven months
after transplant presented fever, abdominal pain, diarrheashowing predominance of chronic lessions of TMA  and mild
signs of acute TMA with interstitial ﬁbrosis of 5–10% and some
microhemorrhages, with ATN (Fig. 2). New course of 3 daily PE
and ﬁnal dose of 1200 mg  of Eculizumab iv were prescribed.
